Tabor Asset Management LP bought a new position in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The fund bought 8,595 shares of the health services provider's stock, valued at approximately $796,000.
Several other institutional investors also recently made changes to their positions in the stock. Trexquant Investment LP boosted its position in shares of Amedisys by 1,317.8% in the 4th quarter. Trexquant Investment LP now owns 87,719 shares of the health services provider's stock worth $7,964,000 after buying an additional 81,532 shares in the last quarter. Fifth Third Bancorp lifted its holdings in Amedisys by 68.1% in the 1st quarter. Fifth Third Bancorp now owns 348 shares of the health services provider's stock valued at $32,000 after purchasing an additional 141 shares in the last quarter. Teacher Retirement System of Texas purchased a new position in Amedisys in the 1st quarter valued at about $817,000. Schonfeld Strategic Advisors LLC lifted its holdings in Amedisys by 17.5% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 4,500 shares of the health services provider's stock valued at $409,000 after purchasing an additional 671 shares in the last quarter. Finally, Deutsche Bank AG lifted its holdings in shares of Amedisys by 22.7% during the 4th quarter. Deutsche Bank AG now owns 2,524 shares of the health services provider's stock worth $229,000 after acquiring an additional 467 shares during the period. 94.36% of the stock is currently owned by hedge funds and other institutional investors.
Amedisys Stock Performance
Shares of NASDAQ AMED traded up $0.05 during midday trading on Friday, reaching $97.52. 19,944 shares of the company traded hands, compared to its average volume of 412,041. Amedisys, Inc. has a 52 week low of $82.15 and a 52 week high of $98.95. The stock has a 50-day moving average price of $95.97 and a 200 day moving average price of $93.69. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.29 and a quick ratio of 1.29. The company has a market cap of $3.20 billion, a price-to-earnings ratio of 35.98, a PEG ratio of 1.32 and a beta of 0.94.
Amedisys (NASDAQ:AMED - Get Free Report) last released its earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.13 by $0.12. The firm had revenue of $594.78 million for the quarter, compared to analyst estimates of $597.43 million. Amedisys had a return on equity of 12.52% and a net margin of 3.79%. Amedisys's revenue was up 4.1% compared to the same quarter last year. During the same period in the previous year, the company earned $1.03 earnings per share. Sell-side analysts anticipate that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of Amedisys from a "strong-buy" rating to a "buy" rating in a research report on Saturday, May 24th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $100.00 price objective on shares of Amedisys in a report on Wednesday, April 16th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $100.75.
View Our Latest Research Report on AMED
Amedisys Company Profile
(
Free Report)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amedisys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.
While Amedisys currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
